News
MRNA
--
0.00%
--
New coronavirus variant could be more deadly
The new COVID-19 strain first found in the U.K. may be associated with higher mortality, the U.K. Prime Minister Boris Johnson has said citing early research."In addition to spreading more quickly,
Seekingalpha · 1h ago
WHO panel to issue recommendations on Moderna vaccine next week
reuters.com · 6h ago
39.9 mln doses of COVID-19 vaccines distributed, 19.1 mln administered: U.S. CDC
reuters.com · 8h ago
CDC Changes Vaccine Guidance To OK Mixing Pfizer And Moderna
-CNBC
CNBC · 8h ago
Coronavirus update: UK variant may be more deadly than previously thought; CDC says second dose can be delayed
Prime Minister Boris Johnson says the variant that originated in the UK could be more deadly than previously thought.
Yahoo Finance · 8h ago
CDC quietly changes Covid vaccine guidance to OK mixing Pfizer and Moderna shots in 'exceptional situations'
The CDC says the two products are not interchangeable, but it added in updated guidance posted Thursday that it's OK to mix the shots in rare circumstances.
CNBC.com · 8h ago
Severe allergic reactions to Moderna vaccine appear rare -CDC report
Severe allergic reactions to Moderna Inc's coronavirus vaccine appear to be quite rare, the U.S. Centers for Disease Control and Prevention (CDC) said on Friday, after over 4 million people had received their first dose.
Reuters · 9h ago
VBI Vaccines (VBIV) Provides Updates on COVID-19 Vaccine
Zacks.com · 9h ago
Astrazeneca says initial EU delivery volumes of Covid vaccine to fall short
AstraZeneca said initial deliveries to the European Union of the Covid-19 vaccine it is developing with Oxford University will fall short of the targeted volumes because of a glitch in production.
Reuters · 10h ago
UPDATE 1-AstraZeneca's initial EU delivery volumes of COVID-19 vaccine to fall short
reuters.com · 10h ago
CDC Finds One in 400,000 Had Anaphylaxis After Moderna Shot
About one in 400,000 recipients of the Moderna Inc. Covid-19 vaccine had a severe allergic reaction to the first shot, according to a study from the U.S. Centers for Disease Control and Prevention released on Friday.
Bloomberg · 10h ago
UK PM Johnson Says All Current Evidence Shows Both Vaccines Remain Effective Against Old, New Variants
-Reuters
Reuters · 11h ago
Pfizer finishes enrolling kids in its COVID-19 vaccine study
reuters.com · 11h ago
Should Inovio Be On Your Buy List As It Tackles A Coronavirus Vaccine?
Investor's Business Daily · 13h ago
Moderna's (MRNA) Coronavirus Vaccine Study Begins in Japan
Zacks · 13h ago
"Delays cost lives": Baltic states seek swift EU approval for AstraZeneca vaccine
reuters.com · 14h ago
Thinking about trading options or stock in Intel Corp, Moderna, Microsoft, Pfizer, or Nvidia?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INTC, MRNA, MSFT, PFE, and NVDA.
PR Newswire - PRF · 14h ago
Johnson & Johnson Aims for 100 Million Vaccine Doses by Spring. The Stock Market Is Counting on It.
More data on the Johnson & Johnson vaccine, expected in the coming days, will have ripple effects across the market.
Barrons.com · 14h ago
Sweden gives 1,000 people COVID-19 shots kept at too low temperature
reuters.com · 14h ago
Where Our Current Covid-19 Vaccination Rate Will Take Us
marketwatch.com · 14h ago
Webull provides a variety of real-time MRNA stock news. You can receive the latest news about Moderna through multiple platforms. This information may help you make smarter investment decisions.
About MRNA
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.
More